Valuation: Pluristem Therapeutics

Market Cap 1.23Cr 1.1Cr 1.03Cr 93.29L 1.76Cr 119.47Cr 1.77Cr 12Cr 4.84Cr 61Cr 4.64Cr 4.53Cr 195.47Cr P/E 2025
-1.39x
P/E 2026 -0.85x
Enterprise Value 3.95Cr 3.52Cr 3.28Cr 2.98Cr 5.63Cr 381.85Cr 5.65Cr 39Cr 15Cr 194.68Cr 15Cr 14Cr 624.73Cr EV / Sales 2025
3,90,78,124x
EV / Sales 2026 4,88,78,101x
Free-Float
57.48%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 54 29/03/2017
Director of Finance/CFO 42 01/12/2022
Chief Operating Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 54 01/02/2015
Director/Board Member 56 06/01/2021
Director/Board Member 64 01/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
+3.38%-1.33% - - 1.23Cr
-2.59%-5.70%+40.86%+83.11% 7.21TCr
+3.23%-13.45%+6.00%+55.77% 4.94TCr
+1.56%+2.07%+5.03%+33.38% 4.72TCr
+0.87%-7.83%+296.82%+657.83% 4.03TCr
+0.39%-0.32%+29.55%+30.83% 4.26TCr
+1.24%-1.20%+0.96%+103.86% 3.98TCr
-2.13%-2.18%+7.51%+50.31% 3.05TCr
+5.32%+0.11%-8.77%-12.81% 2.31TCr
+3.78%+5.71%+16.43%-1.77% 2.11TCr
Average +1.47%-3.91%+43.82%+111.17% 4.07TCr
Weighted average by Cap. +0.74%-4.28%+46.74%+118.77%

Financials

2025 2026
Net sales 1.34 1.19 1.11 1.01 1.91 129.3 1.91 13.36 5.23 65.92 5.02 4.91 211.54 1.02 0.91 0.84 0.77 1.45 98.33 1.46 10.16 3.98 50.13 3.82 3.73 160.87
Net income -2.26Cr -2.02Cr -1.88Cr -1.71Cr -3.22Cr -218.56Cr -3.24Cr -23Cr -8.85Cr -111.43Cr -8.48Cr -8.29Cr -357.58Cr -2.38Cr -2.13Cr -1.98Cr -1.8Cr -3.4Cr -230.54Cr -3.41Cr -24Cr -9.33Cr -117.54Cr -8.95Cr -8.75Cr -377.18Cr
Net Debt 1.34Cr 1.2Cr 1.12Cr 1.02Cr 1.92Cr 130.04Cr 1.93Cr 13Cr 5.26Cr 66Cr 5.05Cr 4.94Cr 212.76Cr 2.71Cr 2.42Cr 2.25Cr 2.05Cr 3.87Cr 262.37Cr 3.88Cr 27Cr 11Cr 133.77Cr 10Cr 9.96Cr 429.26Cr
Logo Pluristem Therapeutics
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-